Literature DB >> 2243088

Mouse beta thalassemia, a model for the membrane defects of erythrocytes in the human disease.

P Rouyer-Fessard1, K Leroy-Viard, C Domenget, A Mrad, Y Beuzard.   

Abstract

The present study describes the pathophysiology, at the cellular level, of the mouse beta thalassemia and shows the pertinence of this model for the human disease. The homozygous state of mouse beta thalassemia is characterized by a clinical syndrome similar to the human beta thalassemia intermedia, but it cannot be explained by the small deficiency in beta chain synthesis. The small pool of unpaired and soluble alpha chains present in mouse reticulocytes contrasts with the large amount of insoluble alpha chains in erythrocytes which is induced by the high instability of mouse alpha chains and the absence of significant proteolysis. The amount of insoluble alpha chains associated with red cell ghosts is similar in human and mouse disease of similar severity. The study of membrane protein defects showed a decreased amount of spectrin (alpha and beta chains) and dramatic changes in the distribution of the most reactive thiol groups of membrane proteins. These results were similar to that previously described in the human disease (Rouyer-Fessard, P., Garel, M. C., Domenget, C., Guetarni, D., Bachir, D., Colonna, P., and Beuzard, Y. (1989) J. Biol. Chem. 264, 19092-19098). Abnormal density distribution curves of erythrocytes and oxidant-induced lysis of red blood cells used as functional tests were similar in the human and mouse beta thalessemia. We conclude from the present study that 1) mouse beta thalassemia is an excellent model for the membrane defects occurring in the human disease; 2) disease expression is not the reflection of the globin chain unbalance only nor of the soluble pool of alpha hemoglobin chain but mainly is a reflection of insoluble alpha chains; and 3) the rate of proteolysis and instability of alpha chains are important factors which must be taken into consideration in the pathophysiology and the clinical heterogeneity of the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243088

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Protein quality control during erythropoiesis and hemoglobin synthesis.

Authors:  Eugene Khandros; Mitchell J Weiss
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

2.  Concomitant inactivation of Rb and E2f8 in hematopoietic stem cells synergizes to induce severe anemia.

Authors:  Tinghui Hu; Seda Ghazaryan; Chandler Sy; Charles Wiedmeyer; Victor Chang; Lizhao Wu
Journal:  Blood       Date:  2012-03-14       Impact factor: 22.113

3.  Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia.

Authors:  P V Browne; O Shalev; F A Kuypers; C Brugnara; A Solovey; N Mohandas; S L Schrier; R P Hebbel
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermedia.

Authors:  Boris E Shmukler; Alicia Rivera; Parul Bhargava; Katherine Nishimura; Edward H Kim; Ann Hsu; Jay G Wohlgemuth; James Morton; L Michael Snyder; Lucia De Franceschi; Marco B Rust; Christian A Hubner; Carlo Brugnara; Seth L Alper
Journal:  Blood Cells Mol Dis       Date:  2019-11-25       Impact factor: 3.039

5.  Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia.

Authors:  Yi Kong; Suiping Zhou; Anthony J Kihm; Anne M Katein; Xiang Yu; David A Gell; Joel P Mackay; Kazuhiko Adachi; Linda Foster-Brown; Calvert S Louden; Andrew J Gow; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

6.  Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.

Authors:  Olivier Negre; Cynthia Bartholomae; Yves Beuzard; Marina Cavazzana; Lauryn Christiansen; Céline Courne; Annette Deichmann; Maria Denaro; Edouard de Dreuzy; Mitchell Finer; Raffaele Fronza; Béatrix Gillet-Legrand; Christophe Joubert; Robert Kutner; Philippe Leboulch; Leïla Maouche; Anaïs Paulard; Francis J Pierciey; Michael Rothe; Byoung Ryu; Manfred Schmidt; Christof von Kalle; Emmanuel Payen; Gabor Veres
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 7.  Animal models of β-hemoglobinopathies: utility and limitations.

Authors:  Bradley McColl; Jim Vadolas
Journal:  J Blood Med       Date:  2016-11-04

8.  Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD.

Authors:  M Trudel; N Saadane; M C Garel; J Bardakdjian-Michau; Y Blouquit; J L Guerquin-Kern; P Rouyer-Fessard; D Vidaud; A Pachnis; P H Roméo
Journal:  EMBO J       Date:  1991-11       Impact factor: 11.598

9.  Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.

Authors:  Olivier Negre; Anne-Virginie Eggimann; Yves Beuzard; Jean-Antoine Ribeil; Philippe Bourget; Suparerk Borwornpinyo; Suradej Hongeng; Salima Hacein-Bey; Marina Cavazzana; Philippe Leboulch; Emmanuel Payen
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.